Healthcare Sector Beats Nifty 50: Smart Portfolio Move
By Market Desk
Discover why India’s healthcare sector is outperforming the Nifty 50 and how it can be a tactical addition to your investment portfolio.
The healthcare sector has recently demonstrated robust performance, consistently outperforming the Nifty 50 Total Return Index (TRI) across multiple periods. This trend prompts investors to evaluate its strategic position within a diversified portfolio.
Data from the Invesco India Pharma and Healthcare Fund NFO presentation highlights the sector’s significant gains:
- BSE Healthcare TRI delivered 12.5% returns over one year.
- The sector saw 23% returns over three years.
- Over seven years, the BSE Healthcare TRI achieved a 22.7% CAGR.
- Both indices showed broadly similar returns over a 10-year span, with healthcare at 12.7% and Nifty 50 TRI at 12.3%.
Mayank Jain, a Market Analyst at Share.Market by PhonePe, characterizes healthcare as a cyclical, thematic sector. He advises investors to adopt a long-term perspective to navigate its inherent regulatory cycles, export fluctuations, and temporary drawdowns while capitalizing on its structural growth.
Investors seeking exposure have both active and passive fund options. The top 1-year performers in active funds include:
- HDFC Pharma and Healthcare Fund: 25.07%
- Kotak Healthcare Fund: 24.25%
- PGIM India Healthcare Fund: 23.79%
Passive options mentioned are the Nippon India Nifty Pharma ETF and ICICI Prudential Nifty Pharma Index Fund.
Structural Tailwinds Propel Sector
The strong recent performance of the healthcare sector is attributed to several structural factors. These include a growing demand for chronic therapies and expanding domestic healthcare consumption.
Key drivers also include:
- A global shift in the supply chain towards India’s Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) manufacturing.
- Relatively lower valuations observed following the post-2020 market cycle.
Navigating Sectoral Risks
Despite these favorable conditions, investors must acknowledge the inherent risks within the sector. Sectoral funds carry high concentration risk, a crucial consideration for portfolio construction.
Further risks include:
- Sensitivity to global regulatory developments, such as USFDA inspections.
- Potential for valuation stretch, particularly in mid- and small-cap healthcare stocks.
Regarding replacing Nifty 50 funds with healthcare funds, Jain advises against it. He states that healthcare-focused funds are best utilized as